These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36860855)

  • 21. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
    Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
    Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
    Zeng B; Gao L; Zhou Q; Yu K; Sun F
    BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
    Gupta SL; Mantus G; Manning KE; Ellis M; Patel M; Ciric CR; Lu A; Turner JS; O'Halloran JA; Presti RM; Joshi DJ; Ellebedy AH; Anderson EJ; Rostad CA; Suthar MS; Wrammert J
    J Virol; 2022 Sep; 96(17):e0058222. PubMed ID: 35976000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
    Fowlkes AL; Yoon SK; Lutrick K; Gwynn L; Burns J; Grant L; Phillips AL; Ellingson K; Ferraris MV; LeClair LB; Mathenge C; Yoo YM; Thiese MS; Gerald LB; Solle NS; Jeddy Z; Odame-Bamfo L; Mak J; Hegmann KT; Gerald JK; Ochoa JS; Berry M; Rose S; Lamberte JM; Madhivanan P; Pubillones FA; Rai RP; Dunnigan K; Jones JT; Krupp K; Edwards LJ; Bedrick EJ; Sokol BE; Lowe A; McLeland-Wieser H; Jovel KS; Fleary DE; Khan SM; Poe B; Hollister J; Lopez J; Rivers P; Beitel S; Tyner HL; Naleway AL; Olsho LEW; Caban-Martinez AJ; Burgess JL; Thompson MG; Gaglani M
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(11):422-428. PubMed ID: 35298453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Feb; 11(2):176-187. PubMed ID: 36216013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.
    Zhao S; Guo Z; Sun S; Hung CT; Leung EYM; Wei Y; Wang H; Li K; Yam CHK; Chow TY; Gao J; Jia KM; Chong KC; Yeoh EK
    J Clin Virol; 2023 Sep; 166():105547. PubMed ID: 37453162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
    Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
    BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
    Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
    JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
    Chemaitelly H; AlMukdad S; Ayoub HH; Altarawneh HN; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Al-Romaihi HE; Butt AA; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    N Engl J Med; 2022 Nov; 387(20):1865-1876. PubMed ID: 36322837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022.
    Veneti L; Berild JD; Watle SV; Starrfelt J; Greve-Isdahl M; Langlete P; Bøås H; Bragstad K; Hungnes O; Meijerink H
    Int J Infect Dis; 2023 May; 130():182-188. PubMed ID: 36893942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant.
    Eick-Cost AA; Ying S; Wells N
    JAMA Netw Open; 2022 Apr; 5(4):e228071. PubMed ID: 35442453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, Spain.
    Mallah N; Pardo-Seco J; Ares-Gómez S; López-Pérez LR; González-Pérez JM; Rosón B; Otero-Barrós MT; Durán-Parrondo C; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Gómez-Carballa A; Salas A; Martinón-Torres F
    Pediatr Allergy Immunol; 2023 Oct; 34(10):e14037. PubMed ID: 37877845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
    Olson SM; Newhams MM; Halasa NB; Price AM; Boom JA; Sahni LC; Pannaraj PS; Irby K; Walker TC; Schwartz SP; Maddux AB; Mack EH; Bradford TT; Schuster JE; Nofziger RA; Cameron MA; Chiotos K; Cullimore ML; Gertz SJ; Levy ER; Kong M; Cvijanovich NZ; Staat MA; Kamidani S; Chatani BM; Bhumbra SS; Bline KE; Gaspers MG; Hobbs CV; Heidemann SM; Maamari M; Flori HR; Hume JR; Zinter MS; Michelson KN; Zambrano LD; Campbell AP; Patel MM; Randolph AG;
    N Engl J Med; 2022 Feb; 386(8):713-723. PubMed ID: 35021004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.